ALZN ALZN
Company Profile ↓Company Overview
ALZN (ALZN) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -38.36% |
| 6 Months: | -31.58% |
| 3 Months: | +33.64% |
| 1 Month: | +25.44% |
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)64.12 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 45.4% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jul 2020 | Oct 2020 | Jan 2021 | Jul 2021 | Oct 2021 | Jan 2022 | Jul 2022 | Oct 2022 | Jan 2023 | Jul 2023 | Oct 2023 | Jan 2024 | Jul 2024 | Oct 2024 | Jan 2025 | Jul 2025 | Oct 2025 | Jan 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | -1.32M | -1.30M | -1.12M | -2.31M | -3.58M | -2.56M | -3.04M | -3.11M | -5.42M | -3.53M | -2.90M | -2.66M | -962.40K | -1.36M | -1.04M | -2.70M | -998.11K | -2.20M |
| Net Income | -1.32M | -1.35M | -1.12M | -2.32M | -3.60M | -2.57M | -3.04M | -3.11M | -5.43M | -3.53M | -2.91M | -2.66M | -974.41K | -1.36M | -1.04M | -2.70M | -1.00M | -2.20M |
| Diluted EPS | - | - | - | - | - | - | -0.03 | -0.48 | -0.83 | -5.38 | -4.43 | -3.77 | -11.42 | -3.61 | -1.75 | -1.28 | -0.30 | -0.58 |
| R&D Expense | 308.85K | 474.91K | 234.26K | 916.41K | 1.75M | 873.65K | 1.38M | 1.53M | 2.89M | 2.37M | 2.00M | 1.91M | 206.57K | 311.09K | 447.11K | 1.74M | 176.28K | 1.28M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Apr 2020 | Apr 2021 | Apr 2022 | Apr 2023 | Apr 2024 | Apr 2025 | Apr 2026 |
|---|---|---|---|---|---|---|---|
| Operating Income | -4.42M | -4.95M | -12.32M | -14.87M | -9.94M | -4.50M | -8.77M |
| Net Income | -4.41M | -5.05M | -12.36M | -14.88M | -9.95M | -4.51M | -8.77M |
| Diluted EPS | - | - | -0.14 | -22.89 | -132.33 | -11.32 | -2.63 |
| R&D Expense | 1.07M | 1.31M | 5.20M | 7.45M | 6.46M | 1.41M | 3.63M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Apr 2019 | Apr 2020 | Apr 2021 | Apr 2022 | Apr 2023 | Apr 2024 | Apr 2025 | Jan 2026 | Apr 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 1.81M | 2.91M | 14.52M | 5.92M | 631.59K | 4.60M | - | 2.08M |
| Total Equity | 316.92K | 821.71K | 2.01M | 13.35M | 3.05M | -2.59M | 3.97M | 2.20M | 733.21K |
| Cash & Equivalents | 42.61K | 90.28K | 1.93M | 14.06M | 5.14M | 376.05K | 3.95M | - | 710.69K |
| Total Liabilities | - | - | 899.64K | 1.16M | 2.87M | 3.23M | 634.76K | - | 1.35M |
| Current Liabilities | - | 992.31K | 899.64K | 1.16M | 2.87M | - | - | - | - |
Cash Flows (Annual)
Figures in USD.
| Metric | Apr 2020 | Apr 2021 | Apr 2022 | Apr 2023 | Apr 2024 | Apr 2025 | Apr 2026 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -2.35M | -2.71M | -6.61M | -8.92M | -8.27M | -6.57M | -8.07M |
| Investing Cash Flow | 105.00K | 100.92K | -106.46K | - | -147.24K | -300.00K | - |
| Financing Cash Flow | 2.29M | 4.45M | 18.85M | 200 | 3.65M | 10.44M | 4.83M |
Ratios (Annual)
Figures in %.
| Metric | Apr 2020 | Apr 2021 | Apr 2022 | Apr 2023 | Apr 2024 | Apr 2025 | Apr 2026 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - | - |
| ROE % | -536.7% | -250.7% | -92.6% | -488.5% | 383.5% | -113.8% | -1,196.4% |
| ROCE % | -538.4% | -246.0% | -92.3% | -488.3% | - | - | - |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ALZN
Alzamend’s $7.5M Funding Will Continue Alzheimer’s Vaccine Trial - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxNcVN0YkNNaGVfUnFtSmVMYUJERGRhTEkxbkpfZ1JEeXhvRjM4elpQcVNjQXNpQmhneEZoVkp3R244b1RsbnpPWUNCQ19Oam9vWk1mZU9aR1dObi1DandJakhpN1dUSnA1VFdpTjY1M0VDVXNMRW5JMmh3eGZqQk5xcS1VYWRUbWxXd1FSeE…
Alzamend Neuro Received Notice of Noncompliance - TradingView
<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxPMlZSdXIzeHlITXVvLUNQcWZTWURQMjNkeS1IeWRjR0p3bUJaMExpV0h2dXF1aUVpMExGcEp4OUNLMTdGZ2YwRElMR1VIclM4MFRwT1ZOQXRiZTNEQkdZWnVXWmlWaUFacEdpZS1QX25TUVVURXRUTC1sQ1h5ckNWMzFXbGdGY3FWMWFDRm…
Alzamend Neuro secures $7.5M in initial funding tranche - Investing.com South Africa
<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxNN3lzWVJSSHJDM0pLSV9LbUR5bERLLXZ2WTVpb2lxOWdqdkZZRGs4cGdqNk9Ha1hTRkQtUER2MGo0OGswRU4tVUU5UF9BWHFPUTVZZHo2c29oSXBxcDY4cE10emg3aTg4VW9aX1d2Z1RNQmVWQ2dteDNiYk9WeXE0eGJ2dFhkRVBGU2JXbj…
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxNLVI4ZHZzQ3NVLWFtRGRkTEtmTjc2LU5hRURZaG5BbHg4TDNxWWpXblBjXzgyMi16WUdPdHR3aEFtMVl2dkIwdUFXVXRtejV5SmRjVnNEMGl3MHJLdFhGQzVFRTdKX19HRi1KVlZ6dmZIZk5TSmNSTUFWcFNOZ0Z5d0tkS3k4cFN2S2s1YU…
Alzamend Neuro Announces Passing of Board Director - theglobeandmail.com
<a href="https://news.google.com/rss/articles/CBMi0wFBVV95cUxQWDJ0M3pGY1dVZ2JTYjFsckZQem50VzN2OVFMbE5HLVlYaXR1WG5EODYtWlJmeW1GMnZ2Z0dDNXpoUHBEb043RXhCU3JvUXJLbDFQMjFlZEFPTmotR2FMSUstN1hoUHBLYXFGRXc4T0ZlNnhjaGJDRTZLSy1tZXZiWmtFY3NIb0I2REp4Zz…
Alzamend Neuro Inc (ALZN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
<a href="https://news.google.com/rss/articles/CBMiZEFVX3lxTE4wd1lSRjRxNFdGc29GcElVSjQ5bElqZFhfWERHdEJOX2dWa25ySGx6bWkxSnRCMnprM3p2WUE1eFZ0M3oweW14RTh3RWQ1T1lrcDVXaGprTlY4Z0JicGgwNXVSZzM?oc=5" target="_blank">Alzamend Neuro Inc (ALZN) Revenu…
ALZN — Frequently Asked Questions
What is the current share price of ALZN?
As of 2026-08-05 17:25 PDT, ALZN trades at $1.43 on NASDAQ/NYSE. Its 52-week range is $0.86 to $2.62.
What is the P/E ratio of ALZN?
ALZN trades at a trailing price-to-earnings (P/E) ratio of -0.54.
Is ALZN a good stock to buy?
This page provides a data-driven analysis of ALZN, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.